Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

Now Viewing

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Ryan Cain, PA-C, discusses the challenges faced by community oncology practices and health systems in adopting bispecifics. He emphasizes the importance of best practices and patient safety, highlighting the potential gaps and toxicities associated with new therapies.

Ryan suggests key considerations for community organizations, such as ensuring the readiness of emergency rooms and facilities for cytokine release syndrome (CRS) and establishing effective transition of care protocols. The focus on patient safety drives the need for training and education across the healthcare system.

The speaker shares insights into their practice's approach, starting with patient safety and identifying groups for training and education. System outreach becomes crucial, involving various stakeholders like emergency rooms, hospitalist groups, inpatient and infusion nurses, and other doctors. The collaboration aims to create a unified strategy for successful therapy implementation.

Mr. Cain advocates for a comprehensive approach, involving a practice champion to educate different parts of the system. Recognizing the uniqueness of the therapy, he emphasizes the involvement of multiple medical groups beyond oncology, requiring community outreach to ensure coordinated care.

The development of a handoff protocol for the emergency room is highlighted as a critical aspect, ensuring quick and appropriate care for patients in different scenarios. The importance of clear communication, whether via telephone, messaging on the electronic medical record (EMR), or in-person clinic visits, is underscored.

The discussion extends to the handling of transitions of care, with a positive note on the ease of receiving patients back from academic institutions. Ryan acknowledges the necessity of effective communication with other centers, fostering collaboration beyond their own group.

The discussion concludes by emphasizing the upcoming influx of therapies and the need to set up programs in the community. The mention of incorporating an article on the optimization and management of therapies, particularly uveal melanoma, adds a forward-looking perspective, showcasing the continuous evolution and adaptation within the healthcare landscape.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.